Alleo Labs

Alleo Labs is a precision neuroscience company based in San Francisco, California, in the United States. According to its official website, the company is focused on re-engineering the treatment of chronic brain disorders by combining computational biology with brain shuttle technology. Its stated mission is to create first-in-class, durable therapeutics targeting neuroinflammation in Parkinson's disease. The company positions itself at the intersection of computational biology and advanced drug delivery. By pairing data-driven discovery approaches with brain shuttle technology — a class of delivery platforms designed to help therapeutics cross the blood-brain barrier — Alleo Labs aims to address neurological diseases that have historically been difficult to treat. Its initial therapeutic focus is neuroinflammation in Parkinson's disease, a key pathological feature of the condition. Alleo Labs is headquartered in San Francisco, a major hub for biotechnology and life sciences innovation. The company operates as a private entity and is actively seeking partnerships; its website directs interested parties to contact the company at think@alleolabs.com for partnering discussions. As a relatively early-stage or emerging company, detailed public information about Alleo Labs' founding team, funding history, and clinical pipeline is limited. The company's public communications emphasize its scientific approach and mission rather than corporate milestones. It should be distinguished from other entities that may share similar names; this dossier concerns the San Francisco-based neuroscience company.

Alleo Labs is a precision neuroscience company headquartered in San Francisco, California, United States. Public information about the company's founding date, founders, and early history is limited. The company has publicly described its approach as combining computational biology with brain shuttle technology to re-engineer the treatment of chronic brain disorders. Its stated mission is to create first-in-class, durable therapeutics targeting neuroinflammation in Parkinson's disease. This focus places the company within the broader field of neurodegenerative disease research, where neuroinflammation has emerged as a significant area of therapeutic interest. Alleo Labs operates as a private company and actively seeks partnerships, directing potential collaborators to contact it via email. As of the available public record, the company does not appear to have disclosed detailed information about its funding, leadership, or clinical development stages. Its public presence is primarily through its official website, which outlines its scientific approach and mission.

Precision neuroscience company combining computational biology with brain shuttle technology to develop durable therapeutics for chronic brain disorders.

• Therapeutics targeting neuroinflammation in Parkinson's disease

  First-in-class, durable therapeutics aimed at neuroinflammation in Parkinson's disease, developed using computational biology and brain shuttle technology.

1. 1Alleo Labs official websitealleolabs.com
2. 2Alleo Labs (United States) - Wikidatawikidata.org